Literature DB >> 18387438

Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance.

A Selcuk Adabag1, Barry J Maron, Evan Appelbaum, Caitlin J Harrigan, Jacqueline L Buros, C Michael Gibson, John R Lesser, Constance A Hanna, James E Udelson, Warren J Manning, Martin S Maron.   

Abstract

OBJECTIVES: Our aim was to determine whether myocardial fibrosis, detected by cardiovascular magnetic resonance (CMR), represents an arrhythmogenic substrate in hypertrophic cardiomyopathy (HCM).
BACKGROUND: Myocardial fibrosis is identified frequently in HCM; however, the clinical significance of this finding is uncertain.
METHODS: We studied prevalence and frequency of tachyarrhythmias on 24-h ambulatory Holter electrocardiogram (ECG) with regard to delayed enhancement (DE) on contrast-enhanced CMR in 177 HCM patients (age 41 +/- 16 yrs; 95% asymptomatic or mildly symptomatic).
RESULTS: Premature ventricular contractions (PVCs), couplets, and nonsustained ventricular tachycardia (NSVT) were more common in patients with DE than those without DE (PVCs: 89% vs. 72%; couplets: 40% vs. 17%; NSVT: 28% vs. 4%; p < 0.0001 to 0.007). Patients with DE also had greater numbers of PVCs (202 +/- 655 vs. 116 +/- 435), couplets (1.9 +/- 5 vs. 1.2 +/- 10), and NSVT runs (0.4 +/- 0.8 vs. 0.06 +/- 0.4) than non-DE patients (all p < 0.0001); DE was an independent predictor of NSVT (relative risk 7.3, 95% confidence interval 2.6 to 20.4; p < 0.0001). However, extent (%) of DE was similar in patients with and without PVCs (8.2% vs. 9.1%; p = 0.93), couplets (8.5% vs. 8.4%; p = 0.99), or NSVT (8.3% vs. 8.5%; p = 0.35).
CONCLUSIONS: In this large HCM cohort with no or only mild symptoms, myocardial fibrosis detected by CMR was associated with greater likelihood and increased frequency of ventricular tachyarrhythmias (including NSVT) on ambulatory Holter ECG. Therefore, contrast-enhanced CMR identifies HCM patients with increased susceptibility to ventricular tachyarrhythmias.

Entities:  

Mesh:

Year:  2008        PMID: 18387438     DOI: 10.1016/j.jacc.2007.11.071

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  181 in total

1.  Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy.

Authors:  Tetsuo Konno; Dan Chen; Libin Wang; Hiroko Wakimoto; Polakit Teekakirikul; Matthew Nayor; Masataka Kawana; Seda Eminaga; Joshua M Gorham; Kumar Pandya; Oliver Smithies; Francisco J Naya; Eric N Olson; J G Seidman; Christine E Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-05       Impact factor: 11.205

2.  MRI classification of asymmetric septal hypertrophic cardiomyopathy and its relation to the presence of risk factors.

Authors:  Yasuo Amano; Mitsunobu Kitamura; Morimasa Takayama; Masaki Tachi; Shinichiro Kumita
Journal:  Int J Cardiovasc Imaging       Date:  2012-03-04       Impact factor: 2.357

3.  MRI of nonischemic cardiomyopathy.

Authors:  David A Bluemke
Journal:  AJR Am J Roentgenol       Date:  2010-10       Impact factor: 3.959

Review 4.  Nuclear cardiac imaging in hypertrophic cardiomyopathy.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

5.  ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.

Authors:  W Gregory Hundley; David A Bluemke; J Paul Finn; Scott D Flamm; Mark A Fogel; Matthias G Friedrich; Vincent B Ho; Michael Jerosch-Herold; Christopher M Kramer; Warren J Manning; Manesh Patel; Gerald M Pohost; Arthur E Stillman; Richard D White; Pamela K Woodard
Journal:  Circulation       Date:  2010-05-17       Impact factor: 29.690

6.  Evaluation of hypertrophic cardiomyopathy: new horizons for CMR?

Authors:  E E van der Wall; H M Siebelink; J J Bax
Journal:  Neth Heart J       Date:  2010-03       Impact factor: 2.380

Review 7.  ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.

Authors:  W Gregory Hundley; David A Bluemke; J Paul Finn; Scott D Flamm; Mark A Fogel; Matthias G Friedrich; Vincent B Ho; Michael Jerosch-Herold; Christopher M Kramer; Warren J Manning; Manesh Patel; Gerald M Pohost; Arthur E Stillman; Richard D White; Pamela K Woodard
Journal:  J Am Coll Cardiol       Date:  2010-06-08       Impact factor: 24.094

8.  Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy.

Authors:  Lu Fang; Andris H Ellims; Anna L Beale; Andrew J Taylor; Andrew Murphy; Anthony M Dart
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 9.  State-of-the-art narrative review: multimodality imaging in electrophysiology and cardiac device therapies.

Authors:  Balint Laczay; Divyang Patel; Richard Grimm; Bo Xu
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

10.  High signal intensity on T2-weighted cardiac magnetic resonance imaging correlates with the ventricular tachyarrhythmia in hypertrophic cardiomyopathy.

Authors:  Yasuki Hen; Nobuo Iguchi; Haruhiko Machida; Kaori Takada; Yuko Utanohara; Tetsuya Sumiyoshi
Journal:  Heart Vessels       Date:  2012-10-25       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.